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Abstract—The aim of the present study was to investigate whether and which cardiac growth factors are involved in human
hypertrophy, whether growth factor synthesis is influenced by overload type and/or by the adequacy of the hypertrophy,
and the relationships between cardiac growth factor formation and ventricular function. Cardiac growth factor formation
was assessed by measuring aorta-coronary sinus concentration gradient in patients with isolated aortic stenosis (n526)
or regurgitation (n515) and controls (n512). Gene expression and cellular localization was investigated in ventricular
biopsies using reverse transcriptase–polymerase chain reaction and in situ hybridization. Cardiac hypertrophy with
end-systolic wall stress ,90 kdyne/cm2 was associated with a selective increased formation of insulin-like growth factor
(IGF)-I in aortic regurgitation and of IGF-I and endothelin (ET)-1 in aortic stenosis. mRNA levels for IGF-I and
preproET-1 were elevated and mainly expressed in cardiomyocytes. At stepwise analysis, IGF-I formation was
correlated to the mean velocity of circumferential fiber shortening (r50.86, P,0.001) and ET-1 formation to relative
wall thickness (r50.82, P,0.001). When end-systolic wall stress was .90 kdyne/cm2, IGF-I and ET-1 synthesis by
cardiomyocytes was no longer detectable, and only angiotensin (Ang) II was generated, regardless of the type of
overload. The mRNA level for angiotensinogen was high, and the mRNA was exclusively expressed in the interstitial
cells. Ang II formation was positively correlated to end-systolic stress (r50.89, P,0.001) and end-diastolic stress
(r50.84, P,0.001). Multivariate stepwise analysis selected end-systolic stress as the most predictive variable and left
ventricular end-diastolic pressure as the independent variable for Ang II formation (r50.93, P,0.001). In conclusion,
the present results indicate that the course of human left ventricular hypertrophy is characterized by the participation of
different cardiac growth factors that are selectively related both to the type of hemodynamic overload and to
ventricular function. (Circ Res. 1999;85:57-67.)
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Anumber of studies have investigated the mechanismsinvolved in the development of myocardial hypertro-
phy (for review, see References 1 through 4). Evidence has
been presented that hemodynamic overload is the initial
stimulus and that hypertrophy results from the interaction
between mechanical forces and neuroendocrine factors,
leading to an increased cardiac protein synthesis according
to a recapitulation of a fetal pattern of gene expression,
with upregulation of some genes and downregulation of
others.2,3 Studies performed in animal models of hypertro-
phy and cardiac myocytes cultured from neonatal rat hearts
in vitro have shown that a number of factors, including
norepinephrine, angiotensin (Ang), endothelin (ET),
insulin-like growth factor (IGF)-I, interleukin-1b, and
tumor necrosis factor-a (see Reference 5), are involved in,
or are potential stimuli for, myocyte hypertrophy. The
results obtained from cultured myocytes and the experi-
mental models of hypertrophy cannot, however, be easily
extrapolated to human hypertrophy because of species and
developmental stage differences and the large variety in
the duration, extent, observation moment, and types of
hypertrophy. Although studies performed in patients be-
fore and after valve replacement have confirmed that in
humans as well as in animals hemodynamic overload plays
a key role in the occurrence of myocardial hypertrophy,6 – 8
only very little information is available regarding the
cardiac growth factors involved in human hypertrophy. An
increased expression of mRNA for transforming growth
factor-b1 and IGF-I have been reported in idiopathic
hypertrophic cardiomyopathy and in aortic valve stenosis (AS).9
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The present study was therefore planned to investigate the
following: (1) whether cardiac growth factors, specifically
Ang II, ET-1, and IGF-I, which have been found to be more
frequently operating in experimental studies, are also in-
volved in human hypertrophy due to AS or aortic regurgita-
tion (AR); (2) whether gene program synthesis of these
growth factors is modified during the transition from com-
pensated (or adequate), normalizing wall stress, to decom-
pensated (or inadequate) hypertrophy, with elevated wall
stress; and (3) the relationship between cardiac growth factor
formation and left ventricular function.
Materials and Methods
Subjects Investigated
We investigated 41 patients with aortic valve disease (AS, n526;
AR, n515) and left ventricular hypertrophy with stable hemodynam-
ic status and without any clinical signs of heart failure. Patients with
AS were enrolled if aortic valve area (AVA) was ,1 cm2, in the
absence of significant AR. Patients with AR were enrolled when the
regurgitant fraction (RF) was $40% and the valve gradient was
,20 mm Hg.
The control group was made up of 12 normotensive patients who
underwent coronary angiography for atypical chest pain. Angiogra-
phy and routine diagnostic procedures did not reveal any abnormal-
ities. Six patients with mitral stenosis (4 with atrial fibrillation and
increased pulmonary pressure) were also investigated as diseased
controls. All subjects were studied after a week of a normal sodium
diet. Diuretics and/or angiotensin-converting enzyme inhibitors were
withheld a week before the study. The characteristics of patients and
controls are reported in Table 1.
Eighteen patients with AS, 11 with AR, and 4 with mitral stenosis
underwent surgical valve replacement, and myocardial ventricular
biopsies were collected from those patients who gave written
informed consent (9 with AS, 6 with AR, and 4 with mitral stenosis).
Cardiac specimens were also obtained from the explanted hearts of
5 donors (age 4466 years) with no history of cardiac disease who
had been excluded from organ donation for noncardiac reasons
(control hearts).
The protocol of this study complies with the principles of the
Helsinki declaration,10 and all patients gave their informed consent
to participate in the study and to have myocardial biopsies performed
and ventricular specimens used for experimentation. All subjects
underwent a complete clinical and instrumental evaluation for
diagnostic purposes. Coronary artery disease (defined as 50% or
more luminal diameter narrowing of at least 1 major coronary artery
at angiography) was present in 8 patients with AS and 3 with AR,
with 5 and 1, respectively, suffering from stable effort angina.
Patients were excluded if they had development or worsening of
aortic valve disease within the previous 3 months; diastolic blood
pressure .90 mm Hg; a recent history (,6 months) of effort angina,
angina at rest, or myocardial infarction; or echocardiographic evi-
dence of additional valve or congenital heart disease.
The capacity of myocardial hypertrophy for keeping pace with
hemodynamic overload was assessed on the basis of meridional
end-systolic wall stress (ESS). Patients were considered to have
adequate hypertrophy when ESS values were ,90 kdyne/cm2 and to
have inadequate hypertrophy when ESS was .90 kdyne/cm2.11,12
Echocardiographic and
Hemodynamic Measurements
All echocardiographic examinations were performed according to
the American Society of Echocardiography.13 All measurements
were performed prospectively. Left ventricular hypertrophy was
considered to be present if the left ventricular mass, calculated
according to the Devereux formula14 and indexed for body surface
area, was $134 g/m2 for men and 110 g/m2 for women.15
TABLE 1. Main Echocardiographic and Hemodynamic Characteristics of Subjects Investigated
Controls
(n512)
Aortic Stenosis Aortic Regurgitation
Mitral Stenosis
(n56)
Adequate
(n517)
Inadequate
(n59)
Adequate
(n57)
Inadequate
(n58)
Age, y 5767 63610 6369 5566 6267 6368
Aortic gradient, mm Hg z z z 73615 73617 264 567 z z z
Regurgitant fraction, % z z z z z z z z z 5466 5267 z z z
Aortic valve area, cm2 z z z 0.860.2 0.760.1 z z z z z z z z z
Mitral valve area, cm2 z z z 3.960.3 3.860.4 3.460.9 4.360.2 1.060.1
Left ventricular mass, g/m2 110614 189626* 189633* 15064* 205653†‡ 113614
Relative wall thickness, % 3663 5467* 4465†§ 3563 3664 4363†
LVIDDI, cm/m2 2.760.1 2.960.3 3.060.3\ 3.260.1* 3.560.5\ 2.860.2
Vcf, s21 1.1560.18 1.1660.14 0.8760.10†¶ 1.1260.16 0.5660.25*§ z z z
E/A ratio 1.2460.17 1.0560.16\ 0.9260.11† z z z z z z z z z
End-systolic stress, kdyne/cm2 7066 69612 109614*¶ 8264* 115621†‡ 64611
End-diastolic stress, kdyne/cm2 1463 1964† 3566*¶ 3067† 49616†‡ 1168
LVESVI, mL/m2 3264 3167 4469\‡ 3862† 67619†‡ 3666
LVEDVI, mL/m2 8669 78616 99610\§ 109622 138619*‡ 7962
Ejection fraction, % 6364 59610 55610 6368 5269\‡ 5566
LVEDP, mm Hg 861 1963* 2963*¶ 1865* 3066†§ 966
Vcf/LVEDVI 0.01460.003 0.01560.004 0.00960.002†¶ 0.01160.002 0.00460.002*¶ z z z
Vcf/end-systolic stress 0.01760.004 0.01860.004 0.00860.001*¶ 0.01460.002 0.00560.003*¶ z z z
LVIDDI indicates left ventricular internal diastolic dimension index; LVESVI, left ventricular end-systolic volume index.
\P,0.05, †P,0.01, and *P,0.001 vs controls at multiple comparison test; ‡P,0.05, §P,0.01, and ¶P,0.001 vs adequate hypertrophy at multiple comparison
test.
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Relative wall thickness (RWT) was calculated according to the
following formula: RWT5(23PWT)/LVIDD, where PWT is poste-
rior wall thickness and LVIDD is left ventricular internal diastolic
dimension.
The degree of AS was assessed by estimation of AVA, which was
based on the principle of continuity of flow. Specifically, the
cross-sectional area (CSA) at the left ventricular outflow tract
(CSALVOT) was measured with 2-dimensional echocardiography, and
the velocity-time integrals in the left ventricular outflow tract (VLVOT)
and in the AS jet (VAO) were measured with Doppler echocardiog-
raphy, so that AVA was calculated according to the following
formula: AVA5CSALVOT3(VLVOT/VAO).
The maximum transaortic pressure gradient (APG) was calculated
from the maximum aortic jet velocity (Vmax) using the Bernoulli
equation, as follows: APG543(Vmax)2.
AR was assessed by estimation of the RF. Regurgitant stroke
volume (SVREG) was calculated as the difference between total stroke
volume (SVTOT) (calculated as the cross-sectional area of flow times
the velocity-time integral of transvalvular flow across the regurgitant
valve) and forward stroke volume (SVFOR) (calculated as antegrade
flow across a different and nonregurgitant valve). RF was then
calculated as SVREG/SVTOT.
Mitral stenosis was diagnosed when mitral valve area, measured
by either the pressure half-time method or direct planimetry, was
,1.5 cm2, with no or only mild mitral regurgitation at continuous-
wave Doppler echocardiography. Left ventricular systolic function
was evaluated by measuring the ejection fraction and the mean
midwall velocity of circumferential fiber shortening (Vcf), using
Doppler and 2-dimensional echocardiographic data.
The Vcf was calculated as Vcf5FS/ETs, where the fractional
shortening (FS) is [(LVIDD2left ventricular internal systolic dimen-
sion)/LVIDD]3100 and the ejection time (ETs) was derived from the
duration of aortic valve opening. Values of Vcf were normalized by
left ventricular end-diastolic volume index (LVEDVI) and ESS to
evaluate cardiac contractility independently of both preload
(LVEDVI) and end-systolic wall tension (ESS).
Diastolic relaxation was assessed by Doppler evaluation of the
early maximum (E) and atrial (A) left ventricular filling inflow
velocities and their ratio (E/A). Estimates of left ventricular merid-
ional wall stress (WS) were made from M-mode data in combination
with pressure data, using the following formula:
WS50.3343P3LVID/[PWT3(11PWT/LVID)], where P is the left
ventricular pressure and LVID is the left ventricular internal
dimension.
ESS was calculated using systolic blood pressure according to
Reichek et al.12 End-diastolic meridional wall stress (EDS) was
calculated using invasive measurements of left ventricular pressure
taken after the a wave.16
Echocardiographic measurements were read independently by 2
observers unaware of patient identity and of the radioimmunological
assays of cardiac growth factors. Interobserver and intraobserver
variability were 4.160.5% and 2.560.3% for cavity size and
3.760.4% and 2.160.3% for wall thickness, respectively.
Estimation of the Cardiac Production of Growth
Factor Peptides
Patients were premedicated with oral diazepam (10 mg) 1 hour
before the study. After 20 minutes of supine rest and 10 minutes after
catheter positioning, coronary blood flow was measured twice at
5-minute intervals with the thermodilution technique,17 and blood
samples for the determination of cardiac oxygen extraction (arteri-
al-coronary sinus difference) were obtained. Blood samples (10 mL)
for plasma renin activity (PRA) and growth factors assays were
contemporaneously drawn from the aorta, coronary sinus, and
antecubital vein according to procedures previously described.17–19
ET-1, Big ET, and IGF-I Assays
Cardiac formation of ET-1, Big ET, and IGF-I was expressed as the
aorta-coronary sinus concentration gradient indexed by coronary
flow and cardiac mass. Plasma extraction and radioimmunoassay of
ET-1 were performed as previously described.19 The coefficients of
intra-assay and interassay variations were 4% and 10%, respectively.
Big ET was assayed in extracted samples, as for ET-1, by using a
specific rabbit polyclonal antibody (Peninsula Laboratories, Inc).
Intra- and interassay variabilities were 2.8% and 9.7%, respectively.
IGF-I was extracted from acidified plasma samples using dispos-
able chromatographic cartridges (Waters Associated), previously
activated with 60% acetonitrile in 1% trifluoroacetic acid (TFA) in
distilled water (1 mL, once), followed by 1% TFA in distilled water
(3 mL, 3 times). After loading, the column was washed twice with 1
mL of 1% TFA, and the adsorbed peptide was eluted with 3 mL of
60% acetonitrile in 1% TFA. Eluates were dried and stored at
280°C. IGF-I was measured with radioimmunoassay using a spe-
cific rabbit polyclonal antibody (Peninsula Laboratories, Inc). The
IGF-I recovery rate was 9562%. Intra- and interassay variabilities
were 3.5% and 10.3%, respectively. The minimum detectable con-
centration was 1 ng/mL.
Ang I, Ang II, and PRA
Ang I and Ang II cardiac formation was measured by the study of
125I-labeled Ang I kinetics, which provides precise information about
the amount of Ang I de novo formed by a tissue and the total amount
of Ang II resulting both from the conversion of Ang I (arterially
delivered) and from Ang II formed by the tissue.20,21 125I-labeled Ang
I and 125I-labeled Ang II extraction, the fractional conversion rate of
Ang I to Ang II, and cardiac de novo Ang I and Ang II production
Figure 1. Correlation between mean midwall Vcf and ESS in
patients with AS (A) and AR (B).
Figure 2. Big ET, ET-1, IGF-I, and Ang II cardiac formation in
patients with AS, AR, and mitral stenosis (MS). f indicates
healthy controls (C) and controls with MS; F, patients with ade-
quate hypertrophy; and E, patients with inadequate hypertro-
phy, both for AS and for AR. Statistical significance in growth
factor cardiac generation in comparison with control and ade-
quate hypertrophy is reported at the top of columns (*P,0.05 vs
control, $P,0.05 vs adequate hypertrophy at multiple compari-
son test).
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TABLE 2. Univariate and Stepwise Multiple Regression Among Ang II, ET-1, and
IGF-I Cardiac Production and Hemodynamic Parameters
All Patients (n541)
Aortic
Regurgitation
(n515)
Aortic Stenosis
(n526)
r P r P r P
IGF-I
ESS 20.58* 0.001 20.59 0.05 20.49 0.05
AVG 0.28 z z z z z z z z z 0.06 z z z
EDS 20.53 0.001 20.43 z z z 20.48 0.05
LVMI 20.29 z z z 20.46 z z z 0.03 z z z
RWT 0.40 0.01 20.12 z z z 0.68 0.001
LVEDVI 20.47 0.01 20.30 z z z 20.49 0.05
LVESVI 20.63 0.001 20.67 0.01 20.30 z z z
EF 0.33 0.05 0.72 0.01 20.12 z z z
LVEDP 20.45 0.01 20.49 z z z 20.22 z z z
Vcf 0.86* 0.001 0.87* 0.001 0.76* 0.001
E/A ratio z z z z z z z z z z z z 0.32 z z z
Multiple regression
Vcf1ESS 0.89 0.001
ET-1
ESS 20.60 0.001 20.03 z z z 20.64 0.001
AVG 0.58 0.001 z z z z z z 0.16 z z z
EDS 20.59 0.001 0.06 z z z 20.71 0.001
LVMI 20.07 z z z 0.12 z z z 20.29 z z z
RWT 0.82* 0.001 20.28 z z z 0.82* 0.001
LVEDVI 20.55 0.001 20.11 z z z 20.38 z z z
LVESVI 20.41 0.01 20.12 z z z 20.31 z z z
EF 20.02 z z z 0.10 z z z 20.02 z z z
LVEDP 20.39 0.05 0.16 z z z 20.51 0.01
Vcf 0.52 0.001 0.02 z z z 0.68 0.001
E/A ratio z z z z z z z z z z z z 0.63* 0.001
Multiple regression
RWT1E/A ratio 0.87 0.001
Ang II
ESS 0.89* 0.001 0.96* 0.001 0.85* 0.001
AVG 20.16 z z z z z z z z z 0.11 z z z
EDS 0.84 0.001 0.91 0.001 0.84 0.001
LVMI 0.45 0.01 0.92 0.001 20.31 z z z
RWT 20.44 0.01 20.36 z z z 20.49 0.05
LVEDVI 0.61 0.001 0.76 0.001 0.42 0.05
LVESVI 0.80 0.001 0.86 0.001 0.71 0.001
EF 20.49 0.01 20.58 0.05 20.48 0.05
LVEDP 0.88* 0.001 0.89 0.001 0.84* 0.001
Vcf 20.78 0.001 20.79 0.001 20.74 0.001
E/A ratio z z z z z z z z z z z z 20.20 z z z
Multiple regression
ESS1LVEDP 0.93 0.001 0.90 0.001
AVG indicates aortic valve gradient; LVMI, left ventricular mass index; LVESVI, left ventricular
end-systolic volume index; and EF, ejection fraction.
*Independent variable at stepwise regression.
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were used for the evaluation of cardiac 125I-labeled Ang I and
125I-labeled Ang II kinetics. The validity and reliability of these
parameters were confirmed in previous studies.20–22 To calculate the
amount of Ang II formed by PRA during blood transcardiac passage,
we determined the mean transcoronary transit time according to
Gorlin and Storaasli23 in a preliminary study. Ang I and Ang II
concentrations in plasma were measured with radioimmunoassay,
using specific polyclonal antibodies (Peninsula Laboratories, Inc, for
Ang I, and ITS Technogenetic for Ang II), as previously described in
detail.18 Overall intra- and interassay variation coefficients were
6.3% and 12.4% for Ang I and 7.7% and 13.6% for Ang II,
respectively. PRA measurement was performed with a commercial
kit (Sorin Biomedica).
Quantification of Growth Factor mRNA Levels in
the Myocardium
Transmural myocardial biopsies (10 to 20 mg) were obtained from
approximately the same region of the left ventricular free wall.
Bioptic specimens were immediately put in liquid nitrogen and
stored at 280°C until processing. Myocardial levels of preproET-1
(ppET-1), angiotensinogen (AGTN), and IGF-I transcripts were
quantified with reverse transcriptase–polymerase chain reaction
(RT-PCR) using GAPDH as internal standard, according to Li et al.9
Total mRNA was isolated from homogenized frozen samples
using TRIzol reagent (GIBCO-BRL/Life Technologies) as outlined
by the manufacturer and reverse transcribed using oligo(dT).20 PCR
primers were designed according to Li et al9 for GAPDH and IGF-I,
according to Pagotto et al24 for ppET-1 and according to Paul et al25
for AGTN. All primers were purchased from Pharmacia. To ensure
that different amounts of PCRs on myocardial biopsies were not due
to markedly different starting concentrations of mRNA, PCR anal-
ysis was performed for the internal control mRNA (GAPDH) on
serial 2-fold dilutions of cDNA for each sample. The last dilution
giving a positive reaction for GAPDH was used to equalize the
amount of cDNA used in each PCR.
PCR reactions were performed according to Li et al9 in a DNA
thermal cycler (Perkin Elmer Cetus). GAPDH densities and the
growth factor bands were analyzed using a computer image densi-
tometer (Qwin, Leica). The ratio of the growth factor to GAPDH was
determined.
Localization of Growth Factor mRNA in
the Myocardium
The in situ hybridization procedure was performed as previously
described26 using cDNA photobiotin–labeled (Vector Laboratories)
probes for ppET-1 (ET1c, American Type Culture Collection
[ATCC] No. 65698), AGTN (ATCC No. 82996), IGF-I (ATCC No.
59944), and GAPDH (pHcGAP, ATCC No. 57090). Negative
controls were performed by testing the sections with hybridization
mixture (1) without the probe, (2) after incubation with RNase A
(0.05 mg/mL54.7 Kunitz units/mL) for 1 hour at 37°C, and (3) with
application of inappropriate probe (plasmid vector pBR322). Posi-
tive controls were obtained for each sample using a cDNA probe for
the housekeeping gene GAPDH. Myocytes were stained using a
specific anti-human myosin antibody (M8421, Sigma) and a second-
ary fluorescein-conjugated antibody (F4143, Sigma). Each stained
histological section was examined under a microscope (DMRB,
Leica) connected to a computerized image-analysis system (Qwin,
Leica).
Statistical Analysis
Data are expressed as mean6SD. Comparison between groups was
performed using a 1-way ANOVA and Student t test followed by the
Tukey multiple-range comparison test, as appropriate. Univariate
linear relations were analyzed with the Pearson correlation. A
stepwise multiple regression analysis was used for multivariate
re-evaluation of univariate correlations. Variables included in the
stepwise regression analysis were the following: ESS, aortic valve
gradient, EDS, left ventricular mass index, LVEDVI, left ventricular
end-systolic volume index, RWT, left ventricular end-diastolic
pressure (LVEDP), ejection fraction, Vcf, and E/A ratio. The
significance level for univariate and multivariate testing was set at
0.05. All calculations were performed using BMDP statistical
software.
Results
Echocardiographic and Hemodynamic
Characteristics of the Patients
The echocardiographic and hemodynamic characteristics of
the patients are reported in Table 1. The myocardial contrac-
Figure 3. Correlation with IGF-I cardiac formation and Vcf (A)
and ESS (B), between ET-1 cardiac formation and RWT (C), and
between Ang II cardiac formation and ESS (D) in all patients
with AS and AR considered as a whole group.
Figure 4. Top, RT-PCR products of ppET-1, IGF-I, and AGTN
from the myocardium of the hearts of an organ donor (C) and
from patients with AS or AR with adequate (AH) or inadequate
(IH) hypertrophy. LD indicates DNA molecular size markers. At
bottom, the densitometric growth factor/GAPDH ratio is
expressed as a percentage of values obtained in control hearts.
Data are presented as mean6SD.
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tile status (as expressed by the ratios Vcf/LVEDVI and
Vcf/ESS) of all patients except those with adequate hyper-
trophy (ie, with ESS ,90 kdyne/cm2) was significantly
reduced in comparison with controls. Left ventricular rate-
corrected Vcf was linearly and inversely related to ESS in
patients both with AS and AR, but the slopes of the 2
equations indicated an earlier depression of systolic function
at increasing ESS values in patients with AR than in those
with AS (Figure 1).
Plasma Assays of Cardiac Formation of
Growth Factors
IGF-I
In the AR group, cardiac formation of IGF-I was signifi-
cantly increased only in patients with ESS ,90 kdyne/cm2
(Figure 2). Both groups of patients with AS showed a
higher cardiac formation of IGF-I than controls, with
higher values in patients with ESS ,90 kdyne/cm2 than in
those with ESS .90 kdyne/cm2 (P,0.01) (Figure 2). IGF-I
formation was positively related to Vcf at both univariate
and stepwise regression analysis in patients with AR
(r50.87, P,0.001) and in patients with AS (r50.76,
P,0.001) (Table 2). At stepwise analysis with all patients
considered as a whole group, Vcf and ESS were the 2
variables that were independently related to IGF-I forma-
tion (Table 2, Figure 3A and 3B).
ET-1 and Big ET
Only AS patients had significantly higher cardiac formation
of ET-1 and Big ET than controls, with patients with adequate
hypertrophy showing higher values of ET than patients with
inadequate hypertrophy (P,0.01) (Figure 2). At multivariate
stepwise analysis, RWT was the only variable independently
related to ET-1 formation both in the AS patients and in the
whole group (Table 2, Figure 3C). ET-1 formation was not
significantly different in patients with or without effort stable
angina (1.4760.77 versus 0.8860.66 pg/min per gram,
P50.12).
Ang I and Ang II
PRA in controls was 0.7760.17 ng/mL per hour, and no
significant differences were found among the various groups
of patients (F50.76). The aorta-coronary sinus gradient of
Ang I and II in controls and in patients with mitral stenosis
was '0. However, the kinetic study of 125I-labeled Ang I
showed that the de novo formation of Ang I and Ang II on
average balanced out the extraction of Ang I (degradation and
conversion of 125I-labeled Ang I to 125I-labeled Ang II) and the
degradation of Ang II during blood transcardiac passage.
Figure 5. In situ hybridization for
GAPDH (A), IGF-I (B), ppET-1 (C), and
AGTN (D) in myocardial biopsies taken
from the heart of an organ donor
excluded from cardiac donation because
of the mismatch of cardiac size with the
chest of recipient. E and F, Negative
controls obtained after incubation with
RNase A (E) and with plasmid vector
pBR322 (F). Magnification, 3400.
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In all of the patients with ESS ,90 kdyne/cm2, cardiac
Ang formation did not differ from that of controls (Figure
2). Conversely, in all of the patients with ESS .90
kdyne/cm2, regardless of the type of aortic valve disease,
cardiac Ang I formation and conversion of Ang I to Ang II
were notably increased, thus resulting in augmented Ang II
formation (Figure 2). Ang II formation was positively
correlated to ESS (r50.89, P,0.001), EDS (r50.84,
P,0.001), and LVEDP (r50.88, P,0.001) and negatively
to Vcf (r520.78, P,0.001) (Table 2). When multivariate
stepwise analysis was performed, ESS continued to be the
most predictive independent variable for Ang II formation
(Table 2) (Figure 3D). The addition of LVEDP to ESS
significantly improved the correlation (ESS and LVEDP,
r50.93, P,0.001) (Table 2).
RT-PCR Assay of Cardiac Formation of
Growth Factors
RT-PCR data (densitometric ratio of growth factor/GAPDH)
showed that the expression of mRNA for IGF-I in AR hearts
was significantly increased only in adequate hypertrophy
(1.2160.14 [1478% versus control; P,0.005] in adequate
hypertrophy and 0.3160.09 [146% versus control; NS] in
inadequate hypertrophy), whereas in AS it was increased in
both groups (1.2760.1 [1505% versus control] in adequate
hypertrophy and 0.7260.06 [1242% versus control] in inad-
equate hypertrophy; P,0.0001 for both) (Figure 4). The
expression of mRNA for ET-1 was increased only in AS,
especially in adequate hypertrophy (0.6460.02 [1472%
versus control; P,0.0001] in adequate hypertrophy and
0.2660.03 [1132% versus control; P,0.001] in inadequate
hypertrophy) (Figure 4). mRNA for AGTN was overex-
pressed in patients with increased ESS with both AR and AS
(0.3560.03 [1386% versus control; P,0.0001] and
0.3860.04 [1426% versus control; P,0.002], respectively)
(Figure 4).
Hybridization Studies
Negative and positive controls for hybridization showed that
it was specific for mRNA and that the mRNA in the biopsies
was intact (Figures 5 through 8). In the hearts of both healthy
donors and patients with mitral stenosis, mRNA for IGF-I,
ppET-1, and AGTN was expressed only in trace amounts
(Figure 5).
In the specimens from patients with AR who had adequate
hypertrophy, mRNA for IGF-I (Figure 6) was clearly ex-
pressed in myocytes and only mildly in the interstitial cells.
No expression of mRNA for ppET-1 (Figure 7) and AGTN
Figure 6. In situ hybridization for IGF-I
mRNA in myocardial biopsies from
patients with AR (A, B, and E) or AS (C
and D) with adequate (A, C, and E) or
inadequate (B and D) hypertrophy. F,
RNase treatment of the same specimen
of panel E. Magnification: 3400 (A
through D) and 31000 (E and F). A and
E, Positive mRNA signal in cardiomyo-
cytes of a biopsy taken from a patient
with AR and adequate hypertrophy. B,
Negative mRNA expression in AR with
inadequate hypertrophy. C, Positive sig-
nal of mRNA in cardiomyocytes of a
patient with AS and adequate hypertro-
phy. D, Positive signal in interstitial cells
of a patient with AS and inadequate
hypertrophy.
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(Figure 8) was detectable in the cardiomyocytes of this group
of patients. In AS and adequate hypertrophy, mRNA for
ppET-1 was markedly expressed in cardiomyocytes and to a
lesser extent also in vascular wall and interstitial cells (Figure
7C and 7E). In this group of patients, there was an augmented
expression of mRNA for IGF-I in myocytes (Figure 6C).
In patients with AS and inadequate hypertrophy, the
mRNA expression of ppET-1 was almost absent in myocytes,
whereas it was evident in interstitial cells (Figure 7D). mRNA
for IGF-I was undetectable in myocytes and only mildly
expressed by interstitial cells (Figure 6D).
In patients with ESS .90 kdyne/cm2, mRNA expression
for AGTN was notably enhanced in the interstitial cells in
both AR (Figure 8B and 8E) and AS (Figure 8D). In patients
with ESS ,90 kdyne/cm2, regardless of the type of valve
defect, mRNA expression for AGTN was very weak or absent
(Figure 8A and 8C), thus confirming that the increased
synthesis of cardiac angiotensins occurred only in patients
with increased ESS.
Discussion
The present study shows that in humans, (1) left ventricular
hypertrophy is associated with an increased cardiac formation
of several growth factors, (2) growth factors are produced
selectively in relation to the type of hemodynamic overload,
and (3) growth factor formation changes in relation to systolic
wall stress.
Compensatory Hypertrophy and Selective
Formation of Growth Factors
Both the measurements of the active peptides in coronary
sinus blood and the evaluation of mRNA for IGF-I and
ppET-1 by RT-PCR showed that adequate or compensatory
hypertrophy was associated with a selective increase in
cardiac generation of IGF-I (enhanced in both AS and in AR)
and ET-1 (increased only in AS). These findings suggest that
an increase in IGF-I formation is a primary nonselective
cardiac response to increased workload, whereas a more
selective stimulus, such as pressure overload, is required to
enhance ET-1 formation. Evidence has been provided both in
vitro and in vivo that mechanical forces can selectively
regulate gene expression and cause differential induction of
peptide growth factors.27–29 The augmented formation of
IGF-I and ET-1 depends on the increased left ventricle load
and is not related to possible derangements of pulmonary or
peripheral hemodynamics, because no evidence of enhanced
cardiac growth factor formation was found in patients with
mitral stenosis despite the presence of atrial fibrillation,
Figure 7. In situ hybridization for ppET-1
mRNA in myocardial biopsies from
patients with AR (A and B) or AS (C
through E) with adequate (A, C, and E) or
inadequate (B and D) hypertrophy. F,
RNase treatment of the same specimen
as in panel E. Magnification: 3400 (A
through D) and 31000 (E and F). A,
mRNA signal for ppET-1 is detectable
only in endothelial cells in a myocardial
specimen from a patient with AR and
adequate hypertrophy. B, Pale signal of
mRNA expression in interstitial cells in
AR with inadequate hypertrophy. C and
E, Markedly positive signal of mRNA in
cardiomyocytes of a patient with AS and
adequate hypertrophy. D, Markedly posi-
tive signal in interstitial cells of a patient
with AS and inadequate hypertrophy.
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enhanced pulmonary arterial pressure, and increased levels of
circulating ET-1 and Big ET. Likewise, the occurrence of
stable effort angina in the formation of ET-1 and IGF-I seems
to play a minor role, given that no significant differences
were found between patients with and patients without angina
and coronary artery disease.
Hybridization studies showed that IGF-I in patients with
AR was essentially synthesized by myocytes and its forma-
tion was closely associated with preserved ventricular con-
tractility, because IGF-I formation was no longer detectable
when Vcf was reduced. IGF-I directly induces hypertrophy in
isolated cardiomyocytes30 and enhances ventricular hypertro-
phy and myocyte function with no or only a mild increase in
myocardial fibrosis in adult rats.31,32 Constitutive overexpres-
sion of IGF-I in transgenic mice positively influences the
performance of myocytes by enhancing the shortening veloc-
ity and cellular compliance, with consequent improvement of
myocardial response to the Frank-Starling relation.33 Thus,
these properties of IGF-I fit very well with the functional and
morphological characteristics of the hemodynamic compen-
sation of AR, which is substantially a “magnification” type
growth.16 This is borne out by the elongation of sarcomeres
with mild wall thickness, which results in increased left
ventricular volume with a low ratio between myocardial
collagen fiber content and LVEDVI.34 In AS with adequate
hypertrophy, mRNA for IGF-I was mainly expressed by
myocytes and mRNA for ppET-1 by both myocytes and, to a
lesser extent, interstitial cells. In patients with AS, both ET-1
and IGF-I were positively correlated to RWT (r50.82 and
r50.68) and Vcf (r50.68 and r50.76), which suggests a
synergistic role of these peptides in supporting both the
contractility and ventricular wall thickening needed to coun-
terbalance the increased endoventricular systolic pressure.35
Thus, compensatory hypertrophy, regardless of the type of
overload, is sustained by the capacity of myocytes to generate
growth factors endowed with inotropic activity, such as
IGF-I, and, in pressure overload, factors that, besides the
inotropic property, have the capacity for increasing wall
thickness, such as ET-1.
Ang Formation and Transition to Heart Failure
The patients with ESS .90 kdyne/cm2 showed depressed
ventricular contractility, as demonstrated by the low Vcf/
LVEDVI ratio, and biochemically were characterized by a
notable decrease in or even absent generation of IGF-I and
ET-1 by myocytes and by the increase in Ang II generation.
mRNA for these factors was almost exclusively expressed by
interstitial cells. The reduced capacity of myocytes to synthe-
Figure 8. In situ hybridization for AGTN
mRNA in myocardial biopsies from
patients with AR (A, B, and E) or AS (C
and D) with adequate (A and C) and
inadequate hypertrophy (B, D, and E). F,
RNase treatment of the same specimen
of panel E. Magnification: 3400 (A
through D) and 31000 (E and F). A,
mRNA signal is almost undetectable in a
myocardial specimen from a patient with
AR and adequate hypertrophy. B and E,
Signal of mRNA expression is evident in
interstitial cells in AR with inadequate
hypertrophy. C, Almost-undetectable sig-
nal of mRNA in AS with adequate hyper-
trophy. D, Markedly positive signal in
interstitial cells of a patient with AS and
inadequate hypertrophy.
Neri Serneri et al Endothelin, Angiotensin, and IGF-I in Hypertrophy 65
D
ow
nloaded from
 http://ahajournals.org by on July 16, 2019
size IGF-I and ET-1 might be an aspect of phenotype changes
related to the progressive severity of hypertrophy36–38 and,
most importantly, responsible for further depression of con-
tractility. Alternatively, the increased wall stress might inhibit
ET-1 and IGF-I generation and at the same time induce Ang
II formation, given that the mechanical forces acting in
different ways produce different effects on gene expression
and protein synthesis.5,39
In patients with ESS .90 kdyne/cm2, Ang II was the main
growth factor synthesized regardless of the type of hemody-
namic overload, and the generation of Ang II was closely
related to ESS, EDS, and LVEDP. The mRNA for AGTN
was essentially expressed by the interstitial cells (Figure 8).
Of course, the lower sensitivity of in situ hybridization in
comparison with quantitative analysis does not rule out the
possibility that mRNA for AGTN may also be expressed in
cardiomyocytes. The high correlation between Ang II forma-
tion and wall stress suggests that ventricular distension is a
causative factor for Ang II formation in humans, as in isolated
myocytes40,41 and beating hearts.42
Although Ang II has been found to induce myocyte
hypertrophy4 and increased Ang II formation has been fre-
quently observed in experimental models of hypertrophy,43
the hypertrophic response to hemodynamic overload is not
inhibited by Ang blockade,44 and its role in myocardial
hypertrophy is still under debate.45 In the present study, Ang
II formation was not increased in patients with compensated
hypertrophy and was positively correlated to the indices of
reduced ventricular function and ventricular distension. On
the whole, the present results indicate that Ang II is not a
factor for myocardial hypertrophy in humans, but rather a
growth factor that expresses cardiac maladaption to the
increased workload. The participation of Ang II in myocar-
dial hypertrophy may be related mainly to the development of
myocardial fibrosis, as suggested by several in vitro and
experimental studies.46,47 Moreover, the chronically increased
Ang II formation may favor myocyte apoptosis.41,48
In conclusion, the present results indicate that the course of
human myocardial hypertrophy is characterized by the par-
ticipation of different growth factors related both to the type
of hemodynamic overload and to the functional characteris-
tics of the ventricle. The different hemodynamic overload
leads to a selective formation of IGF-I (volume load) or of
both IGF-I and ET-1 (pressure overload), and the ensuing
increased wall stress brings Ang II formation into action. In
addition to pathophysiological significance, these results may
have important clinical implications, because serial echocar-
diographic measurements of ESS in asymptomatic patients
with myocardial hypertrophy allow the timely administration
of angiotensin-converting enzyme inhibitors or other Ang II
antagonists that have been shown49,50 to prevent or delay the
development of contractile dysfunction and the transition to
heart failure in rats and humans.
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